Paris (France), on June 20, 2025. Dear shareholders, We, Mrs. Dominique Costantini, Mr. Emile Loria and Mr. Alexis Peyroles, hereby inform the shareholders of OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) (the “Company”) of recent…
Read allDear OSE Immunotherapeutics Shareholders, As co-founders and former directors of OSE Immunotherapeutics, we intimately understand the company’s innovations, their commercial potential, and the paths to success. We remain major shareholders because we believe in the…
Read allIn order to explain the reasons for the 10 draft resolutions which we have requested to be included on the agenda Dear Shareholders, As co-founders and former directors of OSE Immunotherapeutics, we are concerned about…
Read allLionel Labourdette, PhD Données de la phase de maintenance : des signes positifs mais encore beaucoup de chemin à parcourir Ose Immuno a présenté il y a 2 jours à la DDW les résultats de…
Read allLionel Labourdette, PhD Inflexion de la stratégie, biomarqueur prometteur, différend avec des actionnaires historiques : difficile d'y voir clair à court terme. Nous avons décidé de pendre un peu de recul avant de commenter les…
Read all
English
Français
